Employees: 191
Size CorMedix (CRMD) is a United States Health Care company (Biotechnology) with a market value of $358M, the 2937th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.50 on 18 Nov 2026.
Performance Over six months the shares fell 43.2%, against -31.1% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue grew 92.5% over the last twelve months (peer median +6.8%); the operating margin is 38.6% (peer median -9.8%).
Valuation It trades at 0.4× enterprise value to sales against a peer median of 5.2× (cheapest of 16).
Capital Return on invested capital runs 39.5 points above its cost of capital (10.5% WACC).
Short interest Short interest is 18.2% of the free float (30 Oct 2026).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $412M | $312M | $43.5M | $0 | $65,408 |
| Revenue growth | — | +617% | — | -100% | — |
| Gross profit | $320M | $276M | $40.3M | -$205,562 | -$147,364 |
| EBITDA | $201M | $165M | -$21.9M | -$48.8M | -$30.4M |
| Net income | $63.9M | $163M | -$17.9M | -$46.3M | -$29.7M |
| Free cash flow | $307M | $173M | -$50.7M | -$38.7M | -$24.6M |
| Capital expenditure | $4.92M | $2.26M | $115,730 | $327,300 | $219,360 |
| Total debt | $145M | $149M | $517,013 | $667,632 | $802,433 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CRMD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -40.5% | -2.0% | lowest of 20 |
| 6-month return | -43.2% | -31.1% | 5th lowest of 20 |
| Distance from 52-week high | -65.4% | -49.1% | 5th lowest of 20 |
| Revenue growth (TTM) | +92.5% | +6.8% | 5th highest of 15 |
| Operating margin | 38.6% | -9.8% | highest of 16 |
| EV / Sales | 0.4× | 5.2× | cheapest of 16 |
| ROIC minus cost of capital | +39.5 pp | -9.4 pp | 2nd highest of 16 |
| EV / EBITDA | 0.7× | 16.6× | cheapest of 7 |
| Net debt / EBITDA | -1.1× | -2.9× | 2nd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CorMedix CRMD | United States | $358M | -43% | +92% | 39% | 0.4× | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $363M | -31% | n/a | n/a | n/a | n/a | n/a |
| Medy-Tox 086900.KS | South Korea | $350M | -36% | +3% | 10% | 2.2× | 4.7% | +11.9% |
| Aspen Neuroscience ASPE | United States | $349M | n/a | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $368M | -49% | +179% | 21% | 5.2× | 0.6% | +725.2% |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $370M | -31% | 0% | -4% | 2.6× | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $341M | -19% | -63% | -1,388,360% | 13,911.5× | n/a | n/a |
| GI Innovation 358570.KS | South Korea | $339M | -47% | +1,527% | -918% | 78.5× | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $378M | -15% | -4% | -1,617% | 27.4× | n/a | n/a |
| Larimar Therapeutics LRMR | United States | $337M | -9% | n/a | n/a | n/a | n/a | n/a |
| Alector ALEC | United States | $383M | +21% | +151% | 25% | 1.5× | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $386M | -16% | +6% | -10% | 6.0× | n/a | n/a |
| Medtide 3880.HK | Hong Kong | $331M | -17% | +14% | 36% | 2.4× | n/a | n/a |
| Polynovo PNV.AX | Australia | $388M | -34% | +13% | 5% | 3.9× | 51.9% | +37.6% |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $391M | -20% | +6% | -2% | 1.7× | 36.6% | +8.9% |
| Laekna 2105.HK | Hong Kong | $326M | -53% | n/a | -57% | 4.7× | n/a | n/a |
| C4 Therapeutics CCCC | United States | $325M | -25% | +7% | -316% | 5.4× | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $395M | -41% | -30% | -27% | 5.2× | n/a | n/a |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $396M | -33% | n/a | n/a | n/a | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $321M | -31% | n/a | n/a | n/a | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $319M | -79% | +395% | -173% | 9.5× | n/a | n/a |